Search results for "Anti-bacteria"

showing 10 items of 665 documents

Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.

2013

Summary Concerns have recently emerged about the quality of generic vancomycin products. Our aim is to analyze serum vancomycin concentrations measured 48 hours after the start of an empirical treatment regimen in patients with acute myeloid leukemia (AML) who received one of the two generic vancomycin products available in France. Patients and methods Seventy-nine AML patients treated with vancomycin during two study periods were included in the study. Our vancomycin dosing regimen was based on the patients’ total body weight adjusted for renal clearance. Results A total of 93 serum vancomycin concentrations were collected: 31 in period 1 and 62 in period 2. In bivariate analysis, the mean…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical ScienceKidneyGastroenterologyYoung AdultVancomycinInternal medicinemedicineDrugs GenericHumansIn patientGeneric ProductAgedRetrospective StudiesPharmacologybusiness.industryMyeloid leukemiaSerum concentrationMiddle AgedAnti-Bacterial AgentsRegimenLeukemia Myeloid AcuteImmunologyVancomycinFemaleHemoglobinbusinessmedicine.drugClearanceAnnales pharmaceutiques francaises
researchProduct

Endophthalmitis following penetrating eye injuries

1997

Postinjury endophthalmitis is the eye infection with the worst prognosis. A retrospective 9-year study was made of penetrating eye injuries, with an analysis of the incidence of infection and its relation to the type of wound and the presence of intraocular foreign bodies. There were 403 cases of penetrating eye injury; of these, 233 affected the cornea and 170 involved the posterior pole. Intraocular foreign bodies were present in 40 cases. Endophthalmitis developed in 4.2% of cases (17/403), and was more common in patients with posterior pole involvement (7%) than in purely corneal trauma (2.1%) (p = 0.03, Chi-square). Infection was in turn more frequent in the presence of intraocular for…

AdultMalemedicine.medical_specialtyAdolescentgenetic structuresmedicine.medical_treatmentPosterior poleEyeEye Infections BacterialEye injuriesEndophthalmitisStaphylococcus epidermidisCorneaOphthalmologymedicineUlls InflamacióPenetrating Eye InjuryHumansEvisceration (ophthalmology)AgedEndophthalmitisbiologyBacteriabusiness.industryFungiEye infectionMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisEye Injuries Penetratingeye diseasesSurgeryAnti-Bacterial AgentsOphthalmologymedicine.anatomical_structureEye Foreign BodiesDrug Therapy CombinationFemalesense organsbusinessEye Infections FungalEye Evisceration
researchProduct

The Neutrophil-to-Lymphocyte ratio as a marker of recovery status in patients with severe dental infection.

2017

Background The aim of the study was to assess the value of pretreatment neutrophil/lymphocyte (N/L) ratio and mean platelet volume (MPV) and the correlation between these markers with progression in patients with severe odontogenic infection. Material and Methods A cohort of 100 patients with severe odontogenic infection were divided into 2 groups according to their length of hospital stay. The N/L ratio and MPV was measured in all patients. The correlation in all patients between preoperative fever, preoperative antibiotic doses, postoperative antibiotic doses, total antibiotic doses and hospital stay with N/L ratio and MPV were analyzed. The Youden index was used to identify the optimal c…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classNeutrophilsLymphocyteAntibioticsInfectionsGastroenterologySeverity of Illness Index03 medical and health sciencesLeukocyte CountYoung Adult0302 clinical medicineInternal medicineSeverity of illnessmedicineHumansLymphocytesNeutrophil to lymphocyte ratioMean platelet volumeChildGeneral DentistryRetrospective StudiesOdontogenic infectionOral Medicine and Pathologybusiness.industryResearchRemission InductionRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryAnti-Bacterial Agentsmedicine.anatomical_structureOtorhinolaryngologyTooth Diseases030220 oncology & carcinogenesisCohortUNESCO::CIENCIAS MÉDICASDisease ProgressionSurgeryFemalebusinessMean Platelet VolumeBiomarkersMedicina oral, patologia oral y cirugia bucal
researchProduct

Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches.

1994

We report an alternative dose-finding approach for the selection of optimal prophylactic aminoglycoside dosage in specific (sub)populations of patients. Relative a priori utility of several intervals of gentamicin or tobramycin (AMG) peak and trough serum levels were assigned by a group of pharmacokinetics experts, assuming prophylactic administration for laryngectomy interventions. A group of 27 adult patients, with normal renal function, undergoing elective surgery for laryngeal problems and treated prophylactically with gentamicin (80 mg t.i.d.) or tobramycin (100 mg t.i.d.) was studied. Two blood samples (peak and trough) were drawn at steady-state for AMG assay. Three different methods…

AdultMalemedicine.medical_specialtyDosePremedicationPopulationUrologyPharmacologyPharmacokineticsmedicineTobramycinHumansPharmacology (medical)educationSelection (genetic algorithm)Antibacterial agentAgedPharmacologyAged 80 and overeducation.field_of_studybusiness.industryClindamycinAminoglycosideMiddle AgedAnti-Bacterial AgentsOtorhinolaryngologic NeoplasmsTobramycinGentamicinFemaleGentamicinsbusinessmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

Functional signs in patients consulting for presumed Lyme borreliosis

2019

Little is known about the functional symptoms associated with Lyme borreliosis (LB) in Europe. We aimed to assess functional symptoms associated with presumed LB and to compare patients with and without confirmed LB.We performed a retrospective monocenter study. Patients consulting for presumed LB were included.Between November 2015 and June 2018, 355patients were included (mean age: 51years, 52% of women) of which 48had LB: erythema migrans (42%), early disseminated LB (50%; 35% of neuroborreliosis cases), and late disseminated LB (8%). The most frequently reported functional symptoms were neuropathic pain (23%), arthralgia (23%), and asthenia (17%). Other functional symptoms were rare (≤1…

AdultMalemedicine.medical_specialtyFunctional symptomsDiagnosis Differential03 medical and health sciencesLyme diseasemedicineHumansLyme NeuroborreliosisLyme diseaseIn patientSerologic TestsReferral and ConsultationAgedRetrospective StudiesLyme borreliosis0303 health sciences030306 microbiologyLyme borreliosisbusiness.industryMean ageMiddle Agedmedicine.diseaseDermatology3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesTreatment OutcomeBorrelia burgdorferiNeuropathic painErythema migransErythema Chronicum MigransFemaleFranceSymptom AssessmentbusinessNeuroborreliosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months

2000

Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRecurrenceInterferonInternal medicineRibavirinmedicineHumansInterferon alfaChemotherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C ChronicMiddle AgedRecombinant ProteinsAnti-Bacterial AgentsSurgeryRegimenTreatment OutcomechemistryTolerabilityRNA ViralDrug Therapy CombinationFemaleComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Odontogenic Infections: A 1-year Retrospective Study.

2015

ABSTRACT Objectives The purpose of this study was to analyze the prevalence, demographic patterns and management of odontogenic infections in patients undergoing treatment in an outpatient dental emergency service of a university hospital. Materials and methods In a retrospective study of the year 2012, all patients suffering from odontogenic infections were included. Demographic data, diagnosis and the conducted treatment were analyzed. Odontogenic infections were defined as pulpitis, apical and marginal periodontitis, abscesses and pericoronitis. Results A total of 2,058 out of 4,209 emergency patients suffered from odontogenic infections. The majority (45.0%) had an apical periodontitis,…

AdultMalemedicine.medical_specialtyPericoronitisAdolescentDental emergencyYoung AdultInternal medicineGermanyPrevalenceMedicineHumansPulpitisClinical significanceAbscessChildPeriodontitisGeneral DentistryPeriodontal DiseasesAgedRetrospective StudiesPeriodontitisAged 80 and overbusiness.industryAmoxicillinInfantPulpitisRetrospective cohort studyBacterial InfectionsAmoxicillinMiddle Agedmedicine.diseaseAbscessAnti-Bacterial AgentsTooth DiseasesChild PreschoolFemalePericoronitismedicine.symptombusinessPeriapical Periodontitismedicine.drugThe journal of contemporary dental practice
researchProduct

Efficacy and safety comparison of two amoxicillin administration schedules after third molar removal. A randomized, double-blind and controlled clini…

2009

Objective: The aim of this comparative double-blind, prospective, randomized, clinical trial was to evaluate two amoxicillin administration patterns. The first was a short prophylactic therapy and the second a long postoperative regimen. Study Design: The study population consisted of 160 patients who underwent mandibular third molar extraction. Patients were randomized into two equal groups. In group 1, 2 grams of amoxicillin were administered 1 hour before the procedure and 1 gram 6 hours after surgery. In group 2, patients received 1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hour for 4 days. All patients received the same number of tablets thanks to the use of …

AdultMalemedicine.medical_specialtyPlaceboDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawmedicineHumansProspective StudiesAntibiotic prophylaxisProspective cohort studyGeneral DentistryPostoperative Carebusiness.industryAmoxicillinPain scaleAmoxicillinAntibiotic Prophylaxis:CIENCIAS MÉDICAS [UNESCO]MolarSurgeryAnti-Bacterial AgentsClinical trialRegimenOtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgeryFemalebusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct

Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 y…

2020

Background According to recent estimates 80% of Latvian population is infected with Helicobacter pylori thus their susceptibility to numerous gastric tract diseases is increased. The 1st line H. pylori eradication therapy includes treatment with clarithromycin in combination with amoxicillin or metronidazole and a proton pump inhibitor. However, potential adverse events caused by such therapies to microbiome are insufficiently studied. Objective This study aimed to evaluate the long-term effect of H. pylori eradication on human gastrointestinal tract (GIT) microbiome. Methods The assessment of H pylori eradication impact on GIT microbiome was done by analyzing 120 samples acquired from 60 s…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyHelicobacter Infections03 medical and health sciences0302 clinical medicineInternal medicineClarithromycinClarithromycinMetronidazolemedicineHumansMicrobiomeeducationeducation.field_of_studybiologybusiness.industryGastroenterologyAmoxicillinProton Pump InhibitorsGeneral MedicineHelicobacter pyloriAmoxicillinMiddle Agedbiology.organism_classificationLatviaAnti-Bacterial AgentsGastrointestinal MicrobiomeMetronidazoleInfectious Diseases030220 oncology & carcinogenesis030211 gastroenterology & hepatologyEnterotypeDrug Therapy CombinationFemaleSample collectionbusinessmedicine.drugHelicobacterREFERENCES
researchProduct